393 related articles for article (PubMed ID: 29684570)
21. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
22. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
23. Eosinophils and interleukin-5: the debate continues.
Kay AB; Menzies-Gow A
Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
[No Abstract] [Full Text] [Related]
24. Reslizumab in the treatment of severe eosinophilic asthma: an update.
Walsh GM
Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
[TBL] [Abstract][Full Text] [Related]
25. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
Weir E; Paton J
J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
[No Abstract] [Full Text] [Related]
26. Benralizumab (Fasenra) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
[No Abstract] [Full Text] [Related]
27. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
28. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
[TBL] [Abstract][Full Text] [Related]
30. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
31. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.
Drick N; Seeliger B; Welte T; Fuge J; Suhling H
BMC Pulm Med; 2018 Jul; 18(1):119. PubMed ID: 30021546
[TBL] [Abstract][Full Text] [Related]
32. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
Kurosawa M; Sutoh E
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
[No Abstract] [Full Text] [Related]
33. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
34. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
35. Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma.
d'Ancona G; Kavanagh JE; Dhariwal J; Hearn AP; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Jackson DJ; Kent BD
Allergy; 2021 Jul; 76(7):2238-2241. PubMed ID: 33432682
[No Abstract] [Full Text] [Related]
36. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
Bakakos A; Rovina N; Bakakos P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
[TBL] [Abstract][Full Text] [Related]
37. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
38. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
[TBL] [Abstract][Full Text] [Related]
39. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
Cormier M; Chaboillez S; Lemiere C
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
[No Abstract] [Full Text] [Related]
40. Biological treatment is approved for severe eosinophilic asthma.
Mayor S
BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
